Europe's drugs regulator on Friday recommended changing some terms of the conditional approval given to antiviral drug remdesivir as a COVID-19 treatment, to make clear the conditions under which it can be used.
Europe's drugs regulator on Friday recommended changing some terms of the conditional approval given to antiviral drug remdesivir as a COVID-19 treatment, to make clear the conditions under which it can be used.
Two leading local pharmaceutical firms, LG Chem and SK Bioscience, have recently ended joint sales agreements with Daewoong Pharmaceutical, industry sources said.
We randomly assigned 870 patients who had resected stage III melanoma with BRAF V600E or V600K mutations to receive 12 months of oral dabrafenib (at a dose of 150 mg twice daily) plus trametinib (2 mg once daily) or two matched placebos.
In this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure.
The RET inhibitor selpercatinib was shown to have durable efficacy with mostly low-grade adverse effects in patients with RET fusion–positive non–small-cell lung cancer.
Alzheimer’s is a progressive brain disease that destroys brain cells, leading to memory loss and impairments in thinking and behavior. These symptoms are severe enough to restrict an individual's daily life and activities.
According to the Centers for Disease Control and Prevention (CDC), Alzheimer’s disease is a type of neurodegenerative illness that, at its mildest, can mean a person has difficulty remembering things. At its most severe, it can result in an almost total inability to respond to the world and other people.
Notably, the advanced liver organoids are able to replicate structural changes that occur during liver injuries induced by drugs and non-alcoholic fatty liver disease (NAFLD).
Belgium based Promethera Biosciences S.A., global innovator in cell-based medicines and liver diseases, and Hao Tian Development Group Limited, a diversified investment holding company
The stock closed at $12.90 Monday and immediately shot up 10%, to a bit more than $14, after the deal was announced right after the market closed.